Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)
2.1900
+0.0600 (2.82%)
Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer patients
The company specializes in the research and development of novel drug candidates that target specific epigenetic mechanisms to combat various forms of cancer. By harnessing the potential of these targeted therapies, Salarius aims to improve treatment outcomes and minimize side effects for patients. The company's approach emphasizes precision medicine, with a commitment to addressing unmet medical needs in oncology through robust scientific innovation and clinical trials.
Salarius Pharmaceuticals (NASDAQSLRX) shares are trading higher Monday after the company announced a merger agreement with Decoy Therapeutics, a privately held biopharmaceutical company.
